LINGO-2 antagonists for treatment of conditions involving motor neurons
The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist. An exemplary method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a composition comprising a LINGO-2 antagonist selected from the group consisting of: (i) a soluble LINGO-2 polypeptide; (ii) a LINGO-2 antibody or antigen-binding fragment thereof; (iii) a LINGO-2 antagonist polynucleotide; (iv) a LINGO-2 aptamer; and (v) a combination of two or more of said LINGO-2 antagonists.
1. A method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a LINGO-2 antagonist, wherein the LINGO-2 antagonist is an antibody or antigen-binding fragment thereof that binds LINGO-2 but does not bind LINGO-1.
2. A method for promoting axonal growth of a motor neuron, comprising contacting said motor neuron with a LINGO-2 antagonist, wherein the LINGO-2 antagonist is an antibody or antigen-binding fragment thereof that binds LINGO-2 but does not bind LINGO-1.
3. A method for promoting survival of a motor neuron in a human subject in need thereof, comprising administering to the human subject an effective amount of a LINGO-2 antagonist, wherein the LINGO-2 antagonist is an antibody or antigen-binding fragment thereof that binds LINGO-2 but does not bind LINGO-1.
4. The method of claim 3 wherein said human subject has been diagnosed with a disease, disorder, or injury involving motor neurons.
5. A method for promoting axonal growth of a motor neuron in a human subject in need thereof, comprising administering to the human subject an effective amount of a LINGO-2 antagonist, wherein the LINGO-2 antagonist is an antibody or antigen-binding fragment thereof that binds LINGO-2 but does not bind LINGO-1.
6. A method for treating a disease, disorder, or injury associated with survival of a motor neuron in a human subject in need thereof comprising administering to the human subject a therapeutically effective amount of a composition comprising a LINGO-2 antagonist, wherein the LINGO-2 antagonist is an antibody or antigen-binding fragment thereof that binds LINGO-2 but does not bind LINGO-1.
7. The method of claim 6 , wherein said disease, disorder, or injury is selected from the group consisting of amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), hereditary spastic paraparesis (HSP), X-linked spinobulbar muscular atrophy (SBMA; Kenney disease), progressive bulbar palsy, pseudo-bulbar palsy, spinal muscular atrophy (SMA), post-polio syndrome (PPS), Huntington's disease, Essential tremor (ET), motor neuron disease, paralysis, and Parkinson's disease.
8. The method of claim 7 , wherein said disease, disorder, or injury is amyotrophic lateral sclerosis (ALS).
9. A method for treating a disease, disorder, or injury associated with axonal growth of motor neurons in a human subject in need thereof comprising administering to the human subject a therapeutically effective amount of a composition comprising a LINGO-2 antagonist, wherein the LINGO-2 antagonist is an antibody or antigen-binding fragment thereof that binds LINGO-2 but does not bind LINGO-1.